Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Leukemia, acute lymphocytic (ALL), child
Stage/Subtype:  untreated childhood acute lymphoblastic leukemia
Country:  U.S.A.
Trial Type:  Treatment
Results 1-23 of 23 for your search:
Start Over
Combination Chemotherapy with or without Rituximab in Treating Younger Patients with Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and under
Trial IDs: ANHL1131, NCI-2012-01963, 2010-019224-31, CDR0000732604, IGR2009/1593, COG-ANHL1131, NCT01595048
Risk-Directed Therapy in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Treatment
Age: 18 and under
Trial IDs: TOTXVI, NCI-2011-01254, NCT00549848
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Supportive care, Treatment
Age: 1 to < 10
Trial IDs: AALL0932, NCI-2011-02599, CDR0000683227, COG-AALL0932, NCT01190930
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1131, NCI-2011-03797, CDR0000706370, COG-AALL1131, U10CA098543, NCT01406756
Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: AALL1231, NCI-2014-00712, NCT02112916
Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2212.00, NCI-2009-01244, NCT00968630
Rasburicase or Allopurinol in Preventing Tumor Lysis Syndrome in Patients with Hematological Malignancies Undergoing Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2010-0284, NCI-2012-01889, NCI-2010-02082, NCT01200485
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Combination Chemotherapy and Ofatumumab in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2010-0708, NCI-2011-01061, NCT01363128
Gabapentin in Treating Pain Caused by Vincristine Sulfate in Younger Patients with Acute Lymphoblastic Leukemia
Phase: Phase II
Type: Supportive care, Treatment
Age: 1 to 18
Trial IDs: TINALL, NCI-2012-00413, NCT01506453
Calaspargase Pegol or Pegaspargase in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 365 days to 18 years
Trial IDs: 11-001, NCI-2012-00825, NCT01574274
Bulk or Fractionated Stem Cell Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II
Type: Treatment
Age: Under 75
Trial IDs: 12-016, NCI-2012-00824, NCT01596257
Safety Study of Cord Blood Units for Stem Cell Transplants
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Genetically Modified T Cells in Treating Patients With B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: CRETI-NH, NCI-2012-00644, 19384-CRETI-NH, H-19384, NCT00608270, NCT00586391
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Phase: No phase specified
Type: Treatment
Age: 365 days and under
Trial IDs: CDR0000570260, NCI-2014-00665, CCLG-LK-2006-10, DCOG-INTERFANT-06, EUDRACT-2005-004599-19, NCT00550992
Clofarabine, Cyclophosphamide, and Etoposide in Treating Patients With Acute Leukemia
Phase: No phase specified
Type: Treatment
Age: 60 and under
Trial IDs: HM2012-05, NCI-2013-00966, 1304M30981, 2011LS158, NCT01677949
Combination Chemotherapy and Rituximab in Treating Younger Patients With B Cell Malignancies
Phase: No phase specified
Type: Treatment
Age: 21 and under
Trial IDs: H-30759, NCI-2013-00985, DA-EPOCH-R, NCT01760226
Partially-Matched Donor Stem Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Phase: No phase specified
Type: Treatment
Age: Not specified
Trial IDs: SCT 0813, NCI-2015-00141, CMH 13H11, CMH SCT 0813, SCT 0813 Haplo, NCT02053545
CD34+ Stem Cell Selection in Treating Younger Patients with Malignant Disease Undergoing Donor Stem Cell Transplant
Phase: No phase specified
Type: Treatment
Age: Under 22
Trial IDs: AAAK8060, NCI-2014-00137, NCT02061800
Individualized High Dose Methotrexate in Treating Younger Patients With Cancer and Significant Risk for Side Effects
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 1 to 22
Trial IDs: H-33119, NCI-2014-00923, NCT02076997
Start Over